

5th ISC INTERNATIONAL CONFERENCE ON CANCER THERAPEUTICS

MOLECULAR TARGETS & CLINICAL APPLICATIONS

2-4 APRIL 2009 BARCELONA, SPAIN

CHAIRS:

Mario Dicato, MD Luxembourg Medical Center Luxembourg, Luxembourg

Eric Van Cutsem, MD, PhD University Hospital Gasthuisberg Leuven, Belgium

CO-CHAIRS:


Ronald Feld, MD Princess Margaret Hospital Toronto, Ontario, Canada

Enrico Mini, MD, PhD University of Florence Florence, Italy

LOCAL CHAIR:

Rafael Rosell, MD Catalan Institute of Oncology Barcelona, Spain

Nagahiro Saijo, MD, PhD National Cancer Center Hospital of Tokyo Tokyo, Japan



IMPORTANT DATES

Discounted Registration Deadline **2 February 2009**

Abstract Submission Deadline **5 February 2009**

Regular Registration Deadline 24 March 2009

3 WAYS TO LEARN:



PRINT materials are produced by Imedex for your reference needs



Ô

ONLINE products are produced by Imedex in 6 user-friendly formats

LIVE meetings are produced by Imedex in 15 countries

Visit www.imedex.com to learn more.



4325 Alexander Drive Alpharetta, Georgia 30022-3740, USA





5th isc international conference on cancer therapeutics **MOLECULAR TARGETS & CLINICAL APPLICATIONS**

2-4 APRIL 2009 **BARCELONA, SPAIN**

Hotel Rey Juan Carlos I

CHAIRS:

Mario Dicato, MD Luxembourg Medical Center Luxembourg, Luxembourg

Eric Van Cutsem, MD, PhD **University Hospital Gasthuisberg** Leuven, Belgium

LOCAL CHAIR:

Rafael Rosell, MD Catalan Institute of Oncology Barcelona, Spain

CO-CHAIRS:

Ronald Feld, MD Princess Margaret Hospital Toronto, Ontario, Canada

Enrico Mini, MD, PhD **University of Florence Florence**, Italy

Nagahiro Saijo, MD, PhD **National Cancer Center Hospital of Tokyo** Tokyo, Japan

SECOND ANNOUNCEMENT

EDUCATION IS THE BEST MEDICINE®

WWW.IMEDEX.COM



5th ISC INTERNATIONAL CONFERENCE ON CANCER THERAPEUTICS MOLECULAR TARGETS & CLINICAL APPLICATIONS

2-4 APRIL 2009 BARCELONA, SPAIN

LETTER FROM CHAIRS

DEAR COLLEAGUES,

Dear Colleagues,

On behalf of the International Society of Chemotherapy (ISC), we are pleased to invite you to the 5th International Conference on Cancer Therapeutics: Molecular Targets & Clinical Applications, 2-4 April, 2009, in Barcelona, Spain. This meeting will be a great opportunity for medical and radiation oncologists, hematologists, and other healthcare professionals involved in the care of patients with cancer from all over the world to share the latest knowledge and views on cancer chemotherapeutics, including molecular targeted agents.

Expert faculty from a wide range of cancer disciplines will participate in the scientific program, and their presentations will provide attendees with information on the latest developments in basic, translational, and clinical research. The general focus of the meeting is to highlight how new information may apply to the treatment of cancer patients in your own institution or practice setting.

We look forward to seeing you in Barcelona on 2-4 April 2009.

Sincerely, Mario Dicato, MD, Chair Eric Van Cutsem, MD, PhD, Chair Rafael Rosell, MD, Local Chair Ronald Feld, MD, Co-Chair Enrico Mini, MD, PhD, Co-Chair Nagahiro Saijo, MD, PhD, Co-Chair

WHO SHOULD ATTEND

This conference is intended for oncologists, hematologists and other healthcare professionals, including nurses and pharmacists, interested in and/or involved in the care of patients with cancer.

CORPORATE SUPPORT

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com

EDUCATIONAL OBJECTIVES

After successful completion of this educational activity, participants should be able to:

- Comment upon recent advances in translational research and how it applies to the prevention, diagnosis, and therapeutic management of cancer
- Highlight emerging data regarding the clinical applications of targeted and systemic therapy in breast cancer and use this knowledge to formulate optimal therapeutic strategies
- Provide an in-depth description of current and emerging therapeutic options including their development and utility in lung cancer management
- Outline developments in the prevention and management of symptoms manifesting from disease complications or treatment side-effects
- Recall essential information regarding targeted molecular pathways, emerging data on current and future agents, and the role of prognostic markers in various gastrointestinal cancers
- Review clinical updates in melanoma and glioblastoma
- Integrate into clinical practice the latest advances in molecular targeted therapy, immunotherapeutic approaches, and strategies to overcome resistance in patients with hematologic malignancies
- Recommend treatment modalities and emerging therapeutic approaches in renal, ovarian, and prostate cancers based upon clinical trial data

This conference is endorsed by the following societies:

Italian Society of Chemotherapy

Spanish Society of Medical Oncology (SEOM)



HOTEL ACCOMMODATIONS

Conference Hotel Hotel Rey Juan Carlos I Avinguda Diagonal 661-671 08028, Barcelona, Spain Tel.: + 34 933 644 030 Fax: + 34 933 644 264 www.hrjuancarlos.com/en/index.html

We invite you to join us in the city of Barcelona and the Hotel Rey Juan Carlos I with its beautiful Mediterranean gardens, outdoor pools, 432 luxury rooms, spa and fitness centre, and much more.

For the convenience of attendees, a limited number of rooms have been reserved until 10 March 2009 at a discounted rate of \in 245 for a single room and \in 275 for a double room. Breakfast is included in the room rate. Room rates do not include tax, currently at 7%. This rate is not guaranteed outside the conference dates or after 10 March 2009.

To reserve your room please contact the Hotel Rey Juan Carlos I reservations department at + 34 933 644 040. To receive the group rate, callers must identify themselves as being with the 5th ISC International Conference on Cancer Therapeutics group. The Hotel Rey Juan Carlos' registration website and form may be accessed via the Imedex website. The information can be found on the accommodations tab for the 5th ISC Conference on Cancer Therapeutics at www.imedex.com. Reservation requests received after 10 March 2009 may not be guaranteed the group rate.

Alternative Hotel Hotel SPA Senator Barcelona Cardenal Reig, 11bis 08028 Barcelona, Spain congresos.bcn@playasenator.com Tel. + 34 932 60 99 08 Fax.+ 34 934 49 30 30

The Hotel SPA Senator Barcelona is located 1.3 km from the Hotel Rey Juan Carlos. This modern, eight-story hotel is located four kilometers from the city centre and 1.5 kilometres from Sants railway station. This eight-floor hotel features 213 air-conditioned guestrooms, all of which include satellite television, complimentary wireless Internet, hi-fis with CD players and complimentary minibars. Adjustable beds come with a selection of pillows and bathrooms include designer toiletries, bathrobes and hair dryers.

For the convenience of attendees, a limited number of rooms have been reserved until 1 February 2009 at a discounted rate of €129.00 for a single room and €149.00 for a double room. Room rates include tax and breakfast. This rate is not guaranteed outside the conference dates or after 1 February 2009.

To reserve your room please contact the Hotel SPA Senator Barcelona reservations department at + 34 932 60 99 08 or visit the hotel's website at www.playasenator.com. To receive the group rate, callers must identify themselves as being with the 5th ISC International Conference on Cancer Therapeutics group and give the reference number 4YEF. Internet users must enter the meeting promotional code: 4YEF. Reservation requests received after 1 February 2009 may not be guaranteed the group rate.

ITALIAN PARTICIPANTS

Fargo International Meetings & Conventions SRL has been appointed as the official agency for government authorization for Italian participants. You may contact them directly at:

Fargo International Meetings & Conventions SRL Via Piattro Maroncelli 44/66, 50137 Firenze, Italy Tel.: +39 055 600 555 Fax: +39 055 609 078

FACULTY

Matti S. Aapro, MD Clinique De Genolier Geneva, Switzerland

Tiziano Barbui, MD Ospedali Riuniti di Bergamo Bergamo, Italy

Joan Bladé, MD University of Barcelona Hospital Clinic Barcelona, Spain

Fortunato Ciardiello, MD, PhD Seconda Università degli Studi di Napoli Naples, Italy

Romano Danesi, MD, PhD University of Pisa Pisa, Italy

Eduardo Diaz-Rubio, MD Hospital Clinico Universitario San Carlos Madrid, Spain

Mario Dicato, MD Luxembourg Medical Center Luxembourg, Luxembourg

Volker Diehl, MD, PhD University Hospital of Cologne Cologne, Germany

Ingo Diel, MD Institute of Gynecological Oncology Mannhiem, Germany


Alexander M.M. Eggermont, MD, PhD Erasmus University Medical Center Daniel Den Hoed Cancer Center Rotterdam. The Netherlands

Ronald Feld, MD Princess Margaret Hospital Toronto, Ontario, Canada

Enriqueta Felip, MD Vall d'Hebron University Hospital Barcelona, Spain

Jørn Herrstedt, MD University of Copenhagen, Herlev, Denmark

Julien Mazières, MD, PhD Toulouse University Toulouse, France



FACULTY CONTINUED

Enrico Mini, MD, PhD University of Florence Florence, Italy

Emilio Montserrat, MD University of Barcelona, **Hospital Clinic** Barcelona, Spain

Rafael Rosell, MD Catalan Institute of Oncology Barcelona, Spain

Nagahiro Saijo, MD, PhD National Cancer Center Hospital of Tokyo Tokyo, Japan

Ramon Salazar, MD L'Hospitalet di Llobregat Catalan Institute of Oncology Barcelona, Spain

Valeria Santini, MD Università degli Studi di Firenze Florence, Italy

John Souglakos, MD, PhD University of Crete Crete, Greece

Roger Stupp, MD University Hospital (CHUV) Lausanne, Switzerland

Josep Tabernero, MD Vall d'Hebron University Hospital Barcelona, Spain

Eric Van Cutsem, MD, PhD University Hospital Gasthuisberg Leuven, Belgium

Jan B. Vermorken, MD, PhD **University Hospital Antwerp** Edegem, Belgium

SCIENTIFIC AGENDA

THURSDAY, 2 APRIL 2009

3:45	Introductory	address

Session I: Translational Cancer Medicine

3635101	n. mansiational cancer medicine
14:00	Patient tailored cancer medicine Speaker invited
14:20	Pharmacogenetics in colorectal cance Enrico Mini, MD, PhD
14:40	EGFR customization in non-squamou cell lung cancer Nagahiro Saijo, MD, PhD
15:00	Topic to be determined
15:20	Discussion
15:50	Coffee break
Sessior	ll: Breast Cancer
16:10	Adjuvant Speaker invited
16:30	Metastatic Speaker invited
16:50	Anti-VEGF: Present and future Speaker invited
17:10	Is there a role for anthracyclins in early breast cancer? <i>Speaker invited</i>
17:30	Is there a minimal therapeutic approach for the clinician? Speaker invited
17:50	Novel agents Speaker invited
18:10	Adjourn
FRID	AY, 3 APRIL 2009

Modera	n III: Lung Cancer Itors: Ronald Feld, MD and Rosell, MD
9:00	Neoadjuvant and adjuvant treatment in early-stage NSCLC Enriqueta Felip, MD
9:20	Moving from bench to bedside for optimizing treatment in lung cancer John Souglakos, MD, PhD
9:40	The clinical relevance of pharmacogenomics of anti-metabolites in NSCLC and other tumors <i>Romano Danesi, MD, PhD</i>
10:00	The contribution of Wnt signaling in NSCLC and potential targeted therapeutic strategies Julien Mazières, MD, PhD

10:20	Customizing chemotherapy and targeted therapies Rafael Rosell, MD		
10:40	Discussion		
11:00	Coffee break		

Session IV: Supportive Care Moderator: Matti S. Aapro, MD

11:20	Antiemetics: State of the art Speaker invited
11:40	Anemia: Erythropoesis stimulating agents Thrombocytopenia <i>Matti S. Aapro, MD</i>
12:00	Bisphosphonates and monoclonal antibodies <i>Ingo Diel, MD</i>
12:20	Mucositis Speaker invited
12:40	Thrombosis in cancer <i>Mario Dicato, MD</i>
13:00	Lunch break

	V: GI Cancer cor: Eric Van Cutsem, MD, PhD		
15:00	Angiogenesis inhibition in colorectal cancer Eduardo Diaz-Rubio, MD		
15:20	EGFR inhibition in colorectal cance <i>Speaker invited</i>		
15:40	Predictive markers in colorectal cancer <i>Josep Tabernero, MD</i>		
16:00	Gastric cancer: Do new biologicals have an impact? <i>Eric Van Cutsem, MD, PhD</i>		
16:20	Neuroendocrine tumours <i>Ramon Salazar, MD</i>		
16:40	GIST Speaker invited		
17:10	Novel agents in GI cancers Fortunato Ciardiello, MD, PhD		
Session VI: Melanoma and Glioma			
17.30	Melanoma: What should the		

17:30	Melanoma: What should the clinician know? Alexander M.M. Eggermont, MD, PhD		
18:00	Glioblastoma <i>Roger Stupp, MD</i>		
18:30	Adjourn		

SATURDAY, 4 APRIL 2009

Session VII: Hematology Moderator: *Mario Dicato, MD*

- 9:00 Imatinib and imatinib resistance Speaker invited
- 9:20 JAK-2: Refinements in myeloproliferative disorders *Tiziano Barbui, MD*
- 9:35 Leukemia: An update and novel agents Speaker invited
- 10:00 Myelodysplastic syndromes Valeria Santini, MD
- 10:20 Coffee break
- 10:40 Non-Hodgkin's lymphoma Volker Diehl, MD, PhD
- 11:10 CLL Emilio Montserrat, MD
- 11:30 Myeloma Joan Bladé, MD
- 12:00 Lunch break

Session VIII: Keynote Lecture

14:00 Cancer stem cells Speaker invited

Session IV: Urogenital Cancer (Kidney/Ovary/Prostate) Moderator: Jan B. Vermorken, MD, PhD

- 14:30 Renal cancer: The new agents Speaker invited
- 14:50 Ovarian cancer: What after platinum resistance? Jan B. Vermorken, MD, PhD
- 15:10 Prostate cancer: New radiotherapeutic modalities Speaker invited
- 15:30 Prostate cancer: Bone metastases, bisphosphonates and others Speaker invited
- 15:50 Prostate cancer: PSA testing: Whom and when, if at all? Speaker invited
- 16:10 Novel agents Speaker invited
- 16:40 Closing remarks and Adjourn

CALL FOR ABSTRACTS

Participants interested in presenting data should submit abstracts online by 5 February 2009. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final meeting summary book and scheduled for poster presentation.

Authors of accepted abstracts who have not registered will have until 24 March 2009 to do so at the rate of €249. After this date, abstracts without registered presenters will be disregarded.

- Follow the online instructions
- Abstracts must be written in English
- Accepted format: Word document format, 9 point Arial font, 500 word count limit
- Use a concise title
- List affiliations of author(s) as briefly as possible, with city, state and country
- Place an asterisk (*) before the name of the presenting author
- Use standard and well-accepted abbreviations
- When using references, use standard and well-accepted formats
- Abstract content should be single-spaced, typed in lower case and contain:
 - Purpose of the study
 - Summarized description
 of the project
 - Results and conclusions

SUBMISSION DEADLINE

5 February 2009

SUBMISSION INSTRUCTIONS

Go to www.imedex.com, select this conference and follow instructions in the "Abstracts" section.



5th isc international conference on cancer therapeutics

MOLECULAR TARGETS & CLINICAL APPLICATIONS

2-4 APRIL 2009 BARCELONA, SPAIN

REGISTRATION FORM

CONFERENCE REGISTRATION		A055.01
FAMILY NAME	GIVEN NAME	MI
	r	
EMAIL ADDRESS		
TELEPHONE	FAX	
INSTITUTE	DEPARTMENT	
ADDRESS		
CITY	STATE / PROVINCE	
ZIP / POSTAL CODE	COUNTRY	

5 Check if you require special facilities or assistance and attach a note with specific details and requirements.

REGISTRATION FEES

□ € 249 Discounted If payment received by 2 February 2009 □ € 449 Full/Onsite If payment received after 24 March 2009

□ € 349 Regular If payment received by 24 March 2009

□ € 75 Nurses/Residents/Students* *proof of eligibility must accompany registration

PAYMENT METHOD

American Express	MasterCard	🗖 Visa	\Box Check or Wire in the amount of: \in _	
Card No.:				_ Expiration Date://
Cardholder's Name:			Signature	

NOTE: Registrants that pay with American Express will be charged in the USD equivalent. This is a policy of American Express. More information may be found at www.oanda.com.

To pay via wire transfer, you must add 50 to each wire transaction to cover bank charges.

To pre-register, registration and payment must be received no later than 24 March 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full.

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 24 March 2009. The amount of registration fees remitted, minus a \in 90 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 24 March 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this conference should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The agenda content is subject to change without notice.

REGISTRATION PROCEDURE

Discounted	€249
If payment received by 2 February 2009	
Regular	€349
If payment received by 24 March 2009	
Full/Onsite	€449
If payment received after 24 March 2009	
Nurses/Residents/Students*	€75
*proof of eligibility must accompany registration	

CONFERENCE LOCATION AND REGISTRATION Barcelona, Spain

Congress Venue

Hotel Rey Juan Carlos I Avinguda Diagonal 661-671 08028, Barcelona, Spain Tel.: + 34 933 644 030 Fax: + 34 933 644 264 www.hrjuancarlos.com/en/index.html

The Registration and Information Desk will be staffed:

Thursday, 2 April 2009 11:30 – 18:00

Friday, 3 April 2009 8:00 – 18:30

Saturday, 4 April 2009 9:00 – 16:30

To Register: You may register online by 24 March 2009 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the Congress.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than 24 March 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the program is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the conference: The 5th ISC International Conference on Cancer Therapeutics: Molecular Targets and Clinical Applications A055.01. An attendee is not registered until full payment is received.

Wire to: Bank of America, NA London, 1 Alie Street E1ADE London UK, Swift Code: BOFAGB22, Sort Code: 165050 Beneficiary: Bank of America Domestic Deposit #5687, Account #: 600895687029, Reference: Imedex, Inc. Account # 10726-118, IBAN: GB89 BOFA 1650 5095 6870 29.

Registration Fee Inclusions:

Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 24 March 2009. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the Conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 24 March 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this Conference should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

CONFERENCE ORGANIZER

🚺 Imedex[®]

4325 Alexander Drive Alpharetta, Georgia 30022-3740, USA Tel..: +1 (770) 751 7332 Fax: +1 (770) 751 7334 Email: meetings@imedex.com www.imedex.com

4 EASY WAYS TO REGISTER





ONLINE... www.imedex.com

EAX US...

+1(678) 242 0920

You can fax your registration 24 hours a day. CALL US... The Registrar will take your registration over the phone. +1 (678) 242 0906



MAIL US...

Imedex[®] 4325 Alexander drive Alpharetta, GA 30022-3740, USA

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda's content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES' RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual's own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

© 2008 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.